A BSTRACT Paroxysmal sympathetic hyperactivity (PSH) affects approximately 27% of severe traumatic brain injury survivors, yet remains challenging to diagnose and manage due to limited high-quality evidence. This critical perspective synthesizes recent advances in PSH identification and management from systematic reviews, meta-analyses, and clinical studies published between 2020 and 2025. The PSH Assessment Measure has emerged as the optimal diagnostic tool, combining clinical feature scoring with diagnostic likelihood assessment to enhance early detection. However, management remains empirical, relying primarily on expert consensus rather than robust clinical trials. Current pharmacotherapy employs combination approaches including benzodiazepines, opioids, beta-blockers, and alpha-2 agonists, though evidence for efficacy varies widely and head-to-head comparisons are absent. This analysis critically evaluates the quality of existing evidence, identifies substantial gaps in understanding PSH pathophysiology and treatment, and emphasizes the urgent need for well-designed randomized controlled trials. We provide practical, evidence-graded recommendations for clinicians while highlighting that current practice standards fall short of evidence-based medicine requirements. Future research priorities include biomarker development, comparative effectiveness trials, standardized outcome measures, and multicenter collaborative studies to establish true evidence-based management strategies.
SASIDHARAN et al. (2026) studied this question.